Metabolon Appoints Chief Scientific Officer
News Nov 09, 2005
Metabolon, Inc. has announced the addition of Dr. Michael Milburn as its Chief Scientific Officer. Dr. Milburn was most recently Senior Vice President of Research and Corporate Development at Sirtris Pharmaceuticals.
“Mike's extensive background and proven leadership ability in drug discovery and development will be valuable as we continue our biomarker discovery projects and expand our business interest into various phases of product development,” said Dr. John Ryals, president and CEO of Metabolon.
Dr. Milburn brings 15 years of experience in biotech and pharmaceutical companies to Metabolon. At Sirtris, he led the preclinical/clinical development of projects in the areas of metabolic disease and neurodegeneration.
Prior to Sirtris, Dr. Milburn was Senior Vice President of Research at Plexxikon, where he was responsible for the development of the company's proprietary high-throughput co-crystallography drug discovery platform.
He has also held positions at Structural Genomix and GlaxoSmithKline. Dr. Milburn received his Ph.D. in Structural Chemistry at the University of California, Berkeley, and was a Research Fellow at Harvard Medical School for his postdoctoral work.
“Metabolon is the leading company in the development and application of metabolomics, and I look forward to building on its success,” said Dr. Milburn.
“Metabolon's ability to identify all of the human metabolites within a disease context or drug effect represents a fast path to identifying new disease diagnostics or alternative therapeutic uses for drug candidates.”
As genome editing technologies advance toward clinical therapies, they are raising hopes of a completely new way to treat disease. However, challenges need to be addressed before potential treatments can be widely used in patients. To tackle these challenges, the National Institutes of Health has launched the Somatic Cell Genome Editing program, which has awarded multiple grants including more than $3.6 million to assess the safety of genome editing in human cells and tissues.